<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618577</url>
  </required_header>
  <id_info>
    <org_study_id>NOAH - AFNET 6</org_study_id>
    <secondary_id>2015-003997-33</secondary_id>
    <nct_id>NCT02618577</nct_id>
  </id_info>
  <brief_title>Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes</brief_title>
  <acronym>NOAH</acronym>
  <official_title>Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised,&#xD;
      multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation&#xD;
      using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism,&#xD;
      or cardiovascular death in patients with AHRE and at least two stroke risk factors but&#xD;
      without AF. The trial will be conducted in several European countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all&#xD;
      available data that demonstrate a beneficial effect of oral anticoagulation for stroke&#xD;
      prevention have been collected in populations with AF documented by conventional ECG&#xD;
      recordings. It is well established that a large proportion of AF episodes remain undiagnosed&#xD;
      (&quot;silent AF&quot;), and many of these patients present with a stroke as the first clinical sign of&#xD;
      AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of&#xD;
      atrial rhythm by implanted devices could close this diagnostic gap. Pacemakers,&#xD;
      defibrillators, and cardiac resynchronisation devices already provide automated algorithms&#xD;
      alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called&#xD;
      &quot;subclinical atrial fibrillation&quot; or, more commonly, &quot;atrial high rate episodes&quot; (AHRE). Data&#xD;
      from large prospectively followed patient cohorts demonstrated that stroke rate is increased&#xD;
      in patients with AHRE. A sizeable portion of these patients develops clinically detected AF&#xD;
      over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal&#xD;
      AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are&#xD;
      lower in patients with AHRE when compared to stroke rates in patients with clinically&#xD;
      diagnosed AF. In light of the bleeding complications associated with oral anticoagulant&#xD;
      therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with&#xD;
      AHREs.&#xD;
&#xD;
      The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better&#xD;
      stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In&#xD;
      addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly&#xD;
      introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favourable profile compared&#xD;
      to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial, edoxaban prevented strokes at&#xD;
      least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3b</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death</measure>
    <time_frame>28 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Components of the primary outcome</measure>
    <time_frame>28 months</time_frame>
    <description>All-cause death Major bleeding events according to the ISTH definitions Quality of life changes at 12 and 24 months compared to baseline Patient satisfaction at 12 and 24 months compared to baseline Cost effectiveness and health resource utilisation Patient autonomy changes at 12 and 24 months compared to baseline including chronic consequences of stroke (aphasia, hemianopia (&quot;mild stroke&quot;)) Cognitive function at 12 and 24 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACEs: cardiac death, myocardial infarction, acute coronary syndrome (ACS), PCI, CABG)</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events according to the International Society on Thrombosis and Haemostasis (ISTH) definitions (60, 61), (Appendix IV)</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life changes at 12 and 24 months compared to baseline (assessed by EQ-5D including its visual-analogue scale and by the Karnofsky scale)</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction at 12 and 24 months compared to baseline (assessed by modified EHRA score (36) and PACT-Q (43))</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness and health resource utilisation estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of autonomy status in patients with stroke during study participation, potentially assessed at each FU visit by modified Rankin scale; a maximum of 2 subsequent assessments in FU per patient with stroke should be performed</measure>
    <time_frame>28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function (MoCA) at 12 and 24 months compared to baseline</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2686</enrollment>
  <condition>Atrial High Rate Episodes</condition>
  <arm_group>
    <arm_group_label>Edoxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:&#xD;
Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:&#xD;
Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.</description>
    <arm_group_label>Edoxaban</arm_group_label>
    <other_name>Lixiana</other_name>
    <other_name>Savaysa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>ASA 100 mg tablets or Placebo</description>
    <arm_group_label>ASA or Placebo</arm_group_label>
    <other_name>ASS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with&#xD;
             feature of detection of AHRE, implanted at least 2 months prior to randomisation&#xD;
&#xD;
          -  AHRE detection feature activated for adequate detection of AHRE (refer to Appendix&#xD;
             XIII)&#xD;
&#xD;
          -  AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device&#xD;
             via its atrial lead and stored digitally. Any AHRE episode recorded is potentially&#xD;
             eligible, but AHRE episodes detected in the first 2 months after implantation of a new&#xD;
             device involving placement or repositioning of atrial electrodes are not eligible.&#xD;
             AHRE episodes recorded in the first two months after a simple &quot;box change&quot; operation,&#xD;
             i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning&#xD;
             of atrial electrodes, are eligible&#xD;
&#xD;
          -  Provision of signed informed consent&#xD;
&#xD;
          -  Age ≥ 65 years&#xD;
&#xD;
        In addition, at least one of the following cardiovascular conditions leading to a modified&#xD;
        CHA2DS2VASc score of 2 or more:&#xD;
&#xD;
          -  Age ≥ 75 years&#xD;
&#xD;
          -  Heart failure (clinically overt or LVEF &lt; 45%)&#xD;
&#xD;
          -  Arterial hypertension (chronic treatment for hypertension, estimated need for&#xD;
             continuous antihyper-tensive therapy or resting blood pressure &gt; 145/90 mmHg)&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Prior stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or&#xD;
             aortic plaques on transesophageal echocardiogram [TEE])&#xD;
&#xD;
          -  Provision of signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease that limits life expectancy to less than 1 year&#xD;
&#xD;
          -  Participation in another controlled clinical trial, either within the past two months&#xD;
             or still ongoing&#xD;
&#xD;
          -  Previous participation in the present trial NOAH - AFNET 6&#xD;
&#xD;
          -  Drug abuse or clinically manifest alcohol abuse&#xD;
&#xD;
          -  Any history of overt AF or atrial flutter&#xD;
&#xD;
          -  Indication for oral anticoagulation (e.g. deep venous thrombosis)&#xD;
&#xD;
          -  Contraindication for oral anticoagulation in general&#xD;
&#xD;
          -  Contraindication for edoxaban as stated in the current SmPC&#xD;
&#xD;
          -  Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a&#xD;
             need for treatment with any antiplatelet agent in addition to edoxaban, especially&#xD;
             dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g.&#xD;
             after receiving a stent) will be eligible when the need for DAPT is no longer present&#xD;
&#xD;
          -  Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt&#xD;
             stroke within 30 days prior to randomisation&#xD;
&#xD;
          -  End stage renal disease (creatinine clearance (CrCl) &lt; 15 ml/min as calculated by the&#xD;
             Cockcroft-Gault method)&#xD;
&#xD;
          -  All persons exempt from participation in a clinical trial by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulus Kirchhof, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham Centre for Cardiovascular Scienes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulus Kirchhof, Prof. Dr.</last_name>
    <phone>+44 121 414</phone>
    <phone_ext>7042</phone_ext>
    <email>p.kirchhof@bham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Blank, Dr.</last_name>
    <phone>0049 251 980</phone>
    <phone_ext>1340</phone_ext>
    <email>benjamin.blank@af-net.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Several Sites</name>
      <address>
        <city>Multiple Locations</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several Sites</name>
      <address>
        <city>Multiple Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several Sites</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Several</name>
      <address>
        <city>Multiple Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <reference>
    <citation>Bertaglia E, Blank B, Blomström-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019 Oct 1;21(10):1459-1467. doi: 10.1093/europace/euz172. Review.</citation>
    <PMID>31377792</PMID>
  </reference>
  <reference>
    <citation>Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.</citation>
    <PMID>28760205</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>atrial high rate episodes</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>VKA</keyword>
  <keyword>NOAC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

